中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1331 records (took 0.048 seconds)

    METHOD FOR IDENTIFYING HIGH-RISK AML PATIENTS
    113.
    发明申请
    METHOD FOR IDENTIFYING HIGH-RISK AML PATIENTS 审中-公开
    识别高风险AML患者的方法

    公开(公告)号：WO2017132749A1

    公开(公告)日：2017-08-10

    申请号：PCT/CA2017/000025

    申请日：2017-02-06

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： WANG, Jean ,  DICK, John ,  NG, Stanley ,  MINDEN, Mark ,  MITCHELL, Amanda ,  CHEN, Weihsu, Claire ,  ZANDSTRA, Peter ,  KENNEDY, James

    IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/04 ,  C40B40/08 ,  G01N33/48 ,  G06F19/10 ,  G06F19/20

    CPC classification number: G01N33/57426 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C40B40/06 ,  C40B40/08 ,  G01N2800/52 ,  G06F19/10 ,  G06F19/20

    Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.

    Abstract translation: 本文描述了预测或分类患有急性骨髓性白血病（AML）的受试者的方法，其包括：（a）确定来自选自以下的对象的测试样品中的至少3个基因的表达水平： 由DNMT3B，ZBTB46，NYNRIN，ARHGAP22，LAPTM4B，MMRN1，DPYSL3，KIAAQ125组成的组。 CDK6，CPXM1，SOCS2，SMIM24，EMP1，NGFRAP1，CD34，AKR1C3，GPR56; 和（b）比较测试样品中至少3种基因的表达与来自一组患者对照样品的至少3种基因的参考表达水平; 其中使用测试样品中至少3种基因的表达和参考表达水平的差异或相似性来预测或分类具有AML的受试者成为低风险组或高风险组以生存更差。

    USE OF ANTIOXIDANTS AS RADIO-PROTECTIVE AGENTS
    118.
    发明申请
    USE OF ANTIOXIDANTS AS RADIO-PROTECTIVE AGENTS 审中-公开
    抗氧化剂作为无机保护剂的使用

    公开(公告)号：WO2016088116A1

    公开(公告)日：2016-06-09

    申请号：PCT/IB2015/059425

    申请日：2015-12-07

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： BARFETT, Joseph ,  MIKULIS, David ,  MURPHY, Kieran P.

    IPC: A61K31/385 ,  A61K31/015 ,  A61K31/198 ,  A61K31/352 ,  A61K31/375 ,  A61P17/16 ,  A61P17/18

    CPC classification number: A61K31/015 ,  A61K9/2004 ,  A61K9/4808 ,  A61K31/198 ,  A61K31/352 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4045 ,  A61K33/00 ,  A61N2005/1094 ,  A61K2300/00

    Abstract: Compositions comprising a radio-protective agent and methods of using such compositions to attenuate or otherwise protect an organism from the adverse effects arising from exposure to ionizing radiation are disclosed. Preferably, the radio-protective agent is an antioxidant and serves to protect the DNA of the organism from damage due to free radicals generated by the ionizing radiation. The methods of use preferably entail determining the timing, duration, and amount of exposure to ionizing radiation and thereby tailoring the administration of the radio-protective agent to protect against the DNA damage expected to arise from such exposure. Potential sources of ionizing radiation include medical imaging (e.g., x-rays, computed tomography, and other techniques in nuclear medicine), radiation therapy, and exposure to radiation in the upper atmosphere (i.e., when flying in an aircraft or space craft).

    Abstract translation: 公开了包含放射性保护剂的组合物和使用这些组合物减弱或以其他方式保护生物免受由于暴露于电离辐射引起的不利影响的方法。 优选地，放射性保护剂是抗氧化剂并且用于保护生物体的DNA免受由电离辐射产生的自由基的损害。 使用的方法优选地需要确定暴露于电离辐射的时间，持续时间和数量，从而定制放射性保护剂的施用以防止由于这种暴露所预期的DNA损伤。 电离辐射的潜在来源包括医学成像（例如，x射线，计算机断层扫描和核医学中的其他技术），放射治疗和暴露于高层大气中的辐射（即在飞机或航天飞机中飞行时）。

Patent Agency Ranking